Literature DB >> 27308591

Novel insights about the MDM2/MDM4 heterodimer.

Fabiola Moretti1.   

Abstract

MDM2 (mouse double minute 2 homolog) and MDM4 (double minute 4 human homolog, also known as MDMX) inhibit the activity of tumor protein p53 (TP53, best known as p53) through their heterodimerization. New evidence indicates that under stress conditions the heterodimer is modified, leading to different activities of the single molecules. In particular, following lethal DNA damage, MDM2 and MDM4 dissociate and MDM4 promotes the stabilization of homeodomain-interacting protein kinase 2 (HIPK2) and the phosphorylation of p53, resulting in transcriptional repression of antiapoptotic targets of p53/HIPK2.

Entities:  

Keywords:  Apoptosis; DNA damage; MDM2; MDM4; heterodimer; p53

Year:  2015        PMID: 27308591      PMCID: PMC4905374          DOI: 10.1080/23723556.2015.1066923

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  9 in total

1.  Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage.

Authors:  Troy W Joseph; Alex Zaika; Ute M Moll
Journal:  FASEB J       Date:  2003-09       Impact factor: 5.191

Review 2.  MDM2's social network.

Authors:  R Fåhraeus; V Olivares-Illana
Journal:  Oncogene       Date:  2013-10-07       Impact factor: 9.867

3.  MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.

Authors:  Giusy Di Conza; Francesca Mancini; Marianna Buttarelli; Alfredo Pontecorvi; Francesco Trimarchi; Fabiola Moretti
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

4.  Regulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damage.

Authors:  Laura A Tollini; Aiwen Jin; Jikyoung Park; Yanping Zhang
Journal:  Cancer Cell       Date:  2014-08-11       Impact factor: 31.743

Review 5.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

6.  Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

Authors:  Yunyuan V Wang; Mathias Leblanc; Mark Wade; Aart G Jochemsen; Geoffrey M Wahl
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

7.  MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway.

Authors:  Francesca Mancini; Giusy Di Conza; Marsha Pellegrino; Cinzia Rinaldo; Andrea Prodosmo; Simona Giglio; Igea D'Agnano; Fulvio Florenzano; Lara Felicioni; Fiamma Buttitta; Antonio Marchetti; Ada Sacchi; Alfredo Pontecorvi; Silvia Soddu; Fabiola Moretti
Journal:  EMBO J       Date:  2009-06-11       Impact factor: 11.598

8.  MDM4 is a key therapeutic target in cutaneous melanoma.

Authors:  Agnieszka Gembarska; Flavie Luciani; Clare Fedele; Elisabeth A Russell; Michael Dewaele; Stéphanie Villar; Aleksandra Zwolinska; Sue Haupt; Job de Lange; Dana Yip; James Goydos; Jody J Haigh; Ygal Haupt; Lionel Larue; Aart Jochemsen; Hubing Shi; Gatien Moriceau; Roger S Lo; Ghanem Ghanem; Mark Shackleton; Federico Bernal; Jean-Christophe Marine
Journal:  Nat Med       Date:  2012-07-22       Impact factor: 53.440

9.  MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.

Authors:  F Mancini; L Pieroni; V Monteleone; R Lucà; L Fici; E Luca; A Urbani; S Xiong; S Soddu; R Masetti; G Lozano; A Pontecorvi; F Moretti
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.